Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
deals
7
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
7
×
startups
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
europe blog main
europe top stories
fda
investing
pfizer
alzheimer's disease
amag pharmaceuticals
astrazeneca
cancer
gilead sciences
What
bio
7
×
roundup
develop
acquisitions
amid
bombast
buy
cancer
caught
ceo
coronavirus
crispr
daniel
debate
discussion
efforts
gilead
meso’s
miss
o’day
pandemic
pfizer’s
presidential
promise
response
sciences
tuesday’s
vaccine
viewers
alliance
announced
available
bails
based
big
biggest
biosciences
brand
bridgebio
bristol
Language
unset
7
×
Current search:
" san francisco top stories "
×
unset
×
bio
×
deals
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More